What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF)?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of SHEZF?

The current price of SHEZF is $0.47. Prices are updated in real time on Stocks360.

What is SHEZF's price-to-earnings (PE) ratio?

SHEZF's trailing twelve-month PE ratio is 185.14, based on current price and earnings per share data available on Stocks360.

What is SHEZF's market capitalization?

SHEZF's market capitalization is $689,042,304.00, placing it in the small-cap tier.

Does SHEZF pay a dividend?

Yes. SHEZF has a trailing twelve-month dividend yield of 0.02%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.47

Market Cap

$689.04M

PE (TTM)

185.14

EPS (TTM)

N/A

Dividend Yield

1.57%

Beta

0.31

Day Range

$0.47 – $0.72

52-wk Range

$0.47 – $0.72

Avg Volume

N/A

Volume

25.00

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) is a publicly traded company in the Healthcare sector. Latest price: $0.47. Market cap $689.04M. Trailing PE 185.14. Dividend yield 1.57%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 7 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $0.47 2026-10-26 · $0.47 (+0.00%)

Earnings

Most Recent

Jun 30, 2025

EPS $0.03 vs est. $0.00

Beat by $0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd., established in 1998 and headquartered in Shenzhen, People's Republic of China, operates as a global pharmaceutical enterprise. Having adopted its current name in February 2017 (formerly Shenzhen Hepalink Pharmaceutical Co.,Ltd.), the company specializes in the production and worldwide distribution of pharmaceutical products across diverse markets including Hong Kong, the United States, Europe, and mainland China. Its comprehensive business operations are structured into four key divisions: finished dose pharmaceutical products, active pharmaceutical ingredients (APIs), contract development and manufacturing organization (CDMO) services, and an 'other' category. Hepalink's product lineup prominently features finished dosage forms such as enoxaparin sodium injection, alongside essential APIs like heparin sodium and enoxaparin sodium, and other specialized APIs including pancreatin. Beyond manufacturing, the firm provides extensive services covering research and development, production, quality control, and program management. It also engages in the innovation and creation of sophisticated biopharmaceuticals, specifically recombinant…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	185.14×
P/S (TTM)	2.37×
P/B	1.12×
P/FCF (TTM)	6.54×
EV / EBITDA	29.54×
EV / Sales	2.65×
Earnings Yield	1.40%
Free Cash Flow Yield	15.30%
Dividend Yield	1.57%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$13.45B
Revenue (TTM)	$5.08B
Net Income (TTM)	$169.04M
Free Cash Flow (TTM)	$1.90B
Net Debt	$1.40B
Working Capital	$5.64B
Gross Margin	33.50%
Operating Margin	8.91%
Net Margin	3.74%
Return on Equity	1.58%
Return on Invested Capital	2.98%